🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

13 results for “Jasper Therapeutics” Clear

  1. Nicotine patch

    Jasper Therapeutics

    Nicotine Dependence

    phase 3 small molecule active

    1 trial

  2. Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  3. Briquilimab

    Jasper Therapeutics

    Chronic Urticaria

    phase 2 small molecule active

    1 trial

  4. Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule terminated

    1 trial

  5. Briquilimab

    Jasper Therapeutics

    Urticaria Chronic

    phase 2 small molecule active

    1 trial

  6. EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule active

    1 trial

  7. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    SCID

    phase 2 mab terminated

    1 trial

  8. Placebo (10 mM sodium acetate, 9.0% (w/v) sucrose, 0.02% (w/v) polysorbate 20, pH 5.2), EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  9. A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma.

    Jasper Therapeutics

    allergic asthma

    phase 1 other active

    1 trial

  10. Briquilimab

    Jasper Therapeutics

    Allergic Asthma

    phase 1 small molecule terminated

    1 trial

  11. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial

  12. JSP191

    Jasper Therapeutics

    Lower-risk Myelodysplastic Syndrome

    phase 1 small molecule terminated

    1 trial

  13. Nelfinavir and Omeprazole

    Jasper Therapeutics

    Healthy Volunteers

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources